APOE genotype     Younger-age AD mutation screen (for patients with symptoms beginning before age 65 years)     Cerebrospinal fluid evaluation for tau and βA-42 analysis     β42 amyloid in the blood. This evidence concerns the gene MAPT and Alzheimer disease.